Wealth Enhancement Advisory Services LLC Purchases 242,237 Shares of Medtronic PLC $MDT

Wealth Enhancement Advisory Services LLC increased its stake in Medtronic PLC (NYSE:MDT) by 42.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 812,251 shares of the medical technology company’s stock after acquiring an additional 242,237 shares during the period. Wealth Enhancement Advisory Services LLC owned about 0.06% of Medtronic worth $79,827,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in MDT. Corundum Trust Company INC bought a new stake in Medtronic in the 3rd quarter worth $27,000. Delos Wealth Advisors LLC bought a new stake in Medtronic during the second quarter worth about $27,000. Steigerwald Gordon & Koch Inc. purchased a new position in Medtronic during the third quarter valued at $33,000. Tripletail Wealth Management LLC purchased a new stake in shares of Medtronic in the third quarter worth $34,000. Finally, Clean Yield Group lifted its stake in shares of Medtronic by 265.7% in the third quarter. Clean Yield Group now owns 384 shares of the medical technology company’s stock worth $37,000 after buying an additional 279 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Trading Down 0.3%

MDT stock traded down $0.26 during midday trading on Tuesday, hitting $96.51. 644,772 shares of the company’s stock were exchanged, compared to its average volume of 6,482,902. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The company has a market cap of $123.72 billion, a PE ratio of 26.04, a price-to-earnings-growth ratio of 2.55 and a beta of 0.71. The stock’s fifty day moving average price is $99.08 and its 200-day moving average price is $94.99. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm’s revenue was up 6.6% compared to the same quarter last year. During the same period last year, the company earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio is presently 76.55%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Stifel Nicolaus lifted their price target on shares of Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Morgan Stanley lifted their target price on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Finally, Robert W. Baird set a $103.00 price target on Medtronic in a report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and an average target price of $110.28.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).